Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 11/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160950 | 1.00 | GPR139 (0.39) | GPR139MEN1KMT2AFEN1PGR | |
| SCHEMBL31358968 | 1.00 | GPR139 (0.39) | GPR139MEN1KMT2AFEN1PGR | |
| SCHEMBL31359138 | 1.00 | GPR139 (0.39) | GPR139MEN1KMT2AFEN1PGR | |
| SCHEMBL31161080 | 0.89 | GPR139 (0.46) | GPR139MEN1KMT2APGR | |
| SCHEMBL31358977 | 0.86 | GPR139 (0.38) | GPR139MEN1KMT2AFEN1PGR | |
| SCHEMBL31359024 | 0.86 | GPR139 (0.38) | GPR139MEN1KMT2AFEN1PGR | |
| SCHEMBL31359112 | 0.86 | MDM2 (0.40) | GPR139MEN1KMT2APPARG | |
| SCHEMBL31359055 | 0.86 | MDM2 (0.40) | GPR139MEN1KMT2APPARG | |
| SCHEMBL31160878 | 0.85 | KMT2A (0.50) | GPR139MEN1KMT2ARECQLPPARG | |
| SCHEMBL31160821 | 0.85 | KMT2A (0.50) | GPR139MEN1KMT2ARECQLPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | GPR139 4045/4885MEN1 2683/4885KMT2A 4427/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | GPR139 3566/4885MEN1 3559/4885KMT2A 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.